Added 10 days ago Drug news

New trial required by FDA for iclaprim, for the treatment of acute bacterial skin and skin structure infections

Motif Bio plc announced that the Company has received the official minutes of the Type A meeting the Company held...

Added 2 months ago Drug news

Motif Bio plc announced new iclaprim data are presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases meeting.

Motif Bio plc announced that new iclaprim data are being presented at the 28th European Congress of Clinical Microbiology and...

Added 4 months ago Drug news

Complete Response Letter for iclaprim to treat acute bacterial skin and skin structure infections.- Motif Bio

Motif Bio plc announced that the Company has received a Complete Response Letter (CRL) from the FDA regarding the New...

Surgical site infections: prevention and treatment

This guideline covers preventing and treating surgical site infections in adults, young people and children who are having a surgical procedure involving a cut through the skin.

Added 10 years ago

Antibiotic prophylaxis in surgery

This guideline provides recommendations based on current evidence for best practice on; the benefits and risks of antibiotic prophylaxis; indications for surgical antibiotic prophylaxis to prevent infection at a range of surgical sites...

Added 10 years ago

Review of oritavancin for the treatment of acute bacterial skin and skin structure infections.

Objective: To assess critically oritavancin, a second-generation  lipoglycopeptide, for the treatment of Acute Bacterial Skin and Skin Structure Infections caused by susceptible Gram-positive bacteria...

Added 11 months ago

Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

Acute bacterial skin and skin structure infections (ABSSSI) are a common disease causing patients to seek treatment through the health care system. With the continued increase of drug-resistant bacterial pathogens, ...

Added 2 years ago

Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic.

Dalbavancin, a recently approved glycopeptide antibiotic, whose disposition is not affected by renal function as compared to vancomycin is used to treat serious infections caused by Staphylococci and Streptococci ...

Added 2 years ago